Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rimantadine · 1 trial · 1 indication
Oseltamivir carboxylate is active metabolite of oseltamivir. AUC0-12 of oseltamivir and oseltamivir carboxylate were calculated following the administration of oseltamivir alone or in combination with rimantadine, using the linear trapezoidal rule.
AUC0-12 of rimantadine was calculated following the administration of rimantadine alone or in combination with oseltamivir, using the linear trapezoidal rule.
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| oseltamivir [Tamiflu] | DRUG | multiple oral doses |
| rimantadine | DRUG | multiple oral doses |
Inclusion Criteria: * Adults, aged 18 to 45 years * Healthy as judged by general physical examination, medical history, vital signs, 12-lead ECG and laboratory tests * Body Mass Index (BMI) 18-34 kg/m2 * Willing not to participate in any other trial including an investigational drug for 3 months fo...
Rimantadine is a small molecule drug being studied for use in healthy volunteers. It is currently in Phase 1 clinical development. The drug is being investigated in a pharmacokinetic study to assess its interaction when co-administered with oseltamivir.
Rimantadine is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this small molecule drug, which is currently in Phase 1 development for use in healthy volunteers.
Rimantadine is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to evaluate its pharmacokinetic properties when taken with oseltamivir.
Rimantadine has one completed clinical trial, NCT01172847, titled 'A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers.' This Phase 1 study enrolled 24 participants in the United States and was active-controlled.
No, rimantadine is not the same as oseltamivir. Rimantadine is a separate investigational drug being studied in combination with oseltamivir, which is marketed as Tamiflu. The clinical trial NCT01172847 evaluates the pharmacokinetics of co-administering these two different drugs.